Navigation Links
Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune

ngoing phase 1 study, MT103/MEDI-538 has shown potent elimination of tumor target cells in peripheral blood, bone marrow, lymph nodes and spleen of therapy- refractory non-Hodgkins lymphoma patients.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. MT103/MEDI-538, which is the first product candidate based on Micromet's novel BiTE(R) product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkins lymphoma. The BiTE product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. Adecatumumab (MT201), a recombinant human monoclonal antibody which targets EpCAM expressing tumors, has completed two phase 2a clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. Micromet has established collaborations with MedImmune, Inc. for MT103/MEDI-538 and Merck Serono for adecatumumab (MT201).

Forward-Looking Statements of Micromet, Inc.

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the intended utilization of product candidates, the conduct and results of future clinical trials, plans regarding regulatory fi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
2. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
4. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
5. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results

Post Your Comments:
(Date:11/6/2009)...OUSTON, Nov. 6 Cyberonic...company will report financial results for the seco...ar ending April 30, 2010 on Wednesday, November 18... conference call to discuss those results on Thurs...cal Year 2010 Second Quarter Results Conference Ca...
(Date:11/6/2009)...ETROIT, Nov. 6 Caraco Ph... has launched ketorolac tromethamine ophthalmic so...S Food and Drug Administration (FDA) for Sun Pharm...neric Acular® opthalmic solution on the first... ketorolac is therapeutically equivalent to Acular...
(Date:11/5/2009)...ATONTOWN, N.J., Nov. 5 O...merging field of biologic products for regenerativ...e third quarter ended September 30, 2009. ,, "D...the release of our three new biologic products Ma...ology and Plexur M® Innovative Grafting," sai...
Breaking Medicine Technology:Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8Gen Probe to Webcast Two Upcoming Investor Presentations 12480 1Gen Probe to Webcast Two Upcoming Investor Presentations 12480 2Maggianos Little Italy 28R 29 Celebrates Sixth Annual Eat A Dish for Make A Wish 28R 29 in Chicago 48012 1Maggianos Little Italy 28R 29 Celebrates Sixth Annual Eat A Dish for Make A Wish 28R 29 in Chicago 48012 2Maggianos Little Italy 28R 29 Celebrates Sixth Annual Eat A Dish for Make A Wish 28R 29 in Chicago 48012 3Maggianos Little Italy 28R 29 Celebrates Sixth Annual Eat A Dish for Make A Wish 28R 29 in Chicago 48012 4Trubion to Present at the 8th Annual Needham Life Sciences Conference 48008 1Trubion to Present at the 8th Annual Needham Life Sciences Conference 48008 2
...armaceuticals,Inc. today announced the issuance of...against human aspartyl (asparaginyl) beta-hydroxyl...nd therapeutic target. These antibodies,were devel...tute of,Technology (MIT) and Panacea has exclusive...of human cancer diagnostics and therapeutics. Pana...
... Evidence Pycnogenol(R) Lowers Joint, Pain, Sympto...g Cessation of the Ext...nter for,Disease Control (CDC), osteoarthritis, th...new study published in the August journal of Phyto...act from the French maritime pine,tree, reduced ov...
Other Medicine Technology:Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4
(Date:11/8/2009)...ov. 8 Pharmaceutical Re... Vice President Ken Johnson released the following...bill: ,, "We are disappointed, but not surprise...ons of hardworking Americans as well as nearly hal...ves who voted against the bill. ,, "While well ...
(Date:11/8/2009)... House Passage of Health Care Reform Bill ,, ...prove coverage for all Americans ,, BALTIMORE,...ght the United States House of Representatives pas...ould strengthen Medicare for seniors and end discr...ons of Americans out of affordable health coverage...
(Date:11/7/2009)... 7 The American Medical...irector of Health at the Family Violence Preventio...e today at its semi-annual policy-making meeting. ...hest honor the AMA House of Delegates bestows on a...om.com/cgi-bin/prnh/20081209/AMALOGO ) ,, "Ms...
(Date:11/7/2009)...thful Catholics have a responsibility to vigorousl... status quo." ,, WASHINGTON, Nov. 7 /PRNews...t Judie Brown released the following statement on ...Speaker Nancy Pelosi,s Affordable Health Care for ...serving the status quo for abortion is voted upon....
(Date:11/7/2009)...sume that all youth will rebel, expert says , ...re more likely to behave badly if their parents ex...ts who believe they are simply being realistic mig...cy," Christy Buchanan, a psychology professor at W...said in a university news release. "Negative expec...
Breaking Medicine News(10 mins):Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AMA Honors Family Violence Prevention Expert 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2
...h Inc. announced today,that it will independently ...ies to outside firms in the pharmaceutical and bio...ue its 23-year collaboration with Pfizer but,will ...d dispersion (SDD) technology,(which increases the...
...y reduces risk of chronic diseases and,can help re...nation, CHICAGO, Oct. 20 Small steps can lead to...lthier Life Steps campaign,launched today. As fami...lthy lifestyle at little or no cost. New,resources...
... less effective, more painful than singular proced...-- Laser therapies to remove unwanted hair may be ...er than in combination, according to an Iranian st...r long-pulsed 755-nanometer alexandrite lasers (12...
...on Plan(TM), Health Management Program to ... U.S. Preventive Medicine(R), the leader,in diseas...fers,Association (AGA Tour), a Lilburn, GA -based .... The Prevention,Plan(TM) is a groundbreaking heal...
...tCall/ - The Westaim Corporation,announced today i...ting,obligations associated with its previous Nasd....S. Securities and Exchange Act of 1934, as,amende...hares will continue to trade on the TSX under the ...
...caling Back Chronic Disease,Initiatives, WASHINGT...sponding to reports that many Americans are forgoi...day called for renewed vigilance,in the fight agai... or carpooling, for example -- we can,t afford to,...
Other Medicine News:Health News:Bend Research Offers Broad Access to Drug-Delivery Solutions 2Health News:AMA Aims to Help Americans Get Healthier One Step at a Time 2Health News:Study Evaluates Laser Therapies for Hair Removal 2Health News:U.S. Preventive Medicine(R) Tees Up with Amateur Golf Association 2Health News:Westaim to deregister its common stock in the United States 2Health News:Nation's Economic Downturn Threatens Continuity of Care for Chronic Conditions 2
PROFILE Titanium Cannulated Interference Screws
PHANTOM SofThread Cannulated Interference Screws
PHANTOM Absorbable Cannulated Interference Screws
Mini Arthroscope
Medicine Products: